New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:43 EDTARGSArgos Therapeutics shares should be bought ahead of data, says JMP Securities
JMP Securities reports that Dr. Figlin, a thought leader in kidney cancer and lead investigator for Argos's pivotal ADAPT study, expects Argos' kidney cancer treatment, AGS-003, to be granted approval timelines that will give it a first-mover advantage. Dr. Figlin believes that AGS-003 and checkpoint inhibitors could move hard-to-tolerate TKI therapies to second line. The firm recommends buying Argos ahead of data for its HIV therapy, AGS-004, which the firm thinks will create a positive read-through for AGS-003.
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
08:36 EDTARGSArgos Therapeutics announces formation of Scientific Advisory Board
Argos Therapeutics announced the formation of the company's first Scientific Advisory Board. Jeff Abbey, president and CEO of Argos, stated, "Forming a scientific advisory board is another important step as we continue to build Argos into a fully-integrated, commercial immuno-oncology company. These oncology and immunology experts will provide us with guidance on many clinical and technical aspects of our development programs. Their input is especially welcome as we continue our pivotal phase 3 ADAPT clinical trial of our lead product candidate, AGS-003, for the treatment of metastatic renal cell carcinoma, and as we plan to begin testing AGS-003 in other tumor types."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use